Literature DB >> 10233984

The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.

K Juhasz1, B R Murphy, P L Collins.   

Abstract

The live-attenuated respiratory syncytial virus vaccine candidate cpts530/1009 was previously shown to contain two separate amino acid changes in the L protein, mutations 530 and 1009 (Phe-521-->Leu and Met-1169-->Val, respectively, according to the amino acid sequence of the L protein). Each mutation independently specifies temperature-sensitive (ts) and attenuation phenotypes. In this study, we examined the effects of these mutations on transcription and RNA replication, using complete infectious recombinant virus as well as a plasmid-based minireplicon system, the latter under conditions in which effects on replication and transcription are uncoupled. In comparison with recombinant wild-type virus, the 530 and 1009 viruses were partially restricted at 37 degrees C for RNA replication, mRNA synthesis, and virus growth. The 1009 virus was partially restricted for RNA synthesis and virus growth even at 32 degrees C, which suggested that the 1009 mutation has a non-ts component in addition to the ts component. Interestingly, the synthesis of polycistronic readthrough mRNAs was elevated 1.6- to 3.8-fold for the 1009 virus, and this defect was non-ts. Studies with the minigenome system showed that the 530 and 1009 mutations each directly affect both replication and transcription, that the effect on replication was marginally greater than on transcription for the 530 mutation, and that the increase in readthrough mRNA associated with the 1009 mutation also was observed with the minigenome system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233984      PMCID: PMC112566     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Low-temperature-grown RS virus in adult volunteers.

Authors:  W T Friedewald; B R Forsyth; C B Smith; M A Gharpure; R M Chanock
Journal:  JAMA       Date:  1968-05-20       Impact factor: 56.272

2.  Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

Authors:  P L Collins; M G Hill; E Camargo; H Grosfeld; R M Chanock; B R Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

3.  Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA.

Authors:  P L Collins; M A Mink; M G Hill; E Camargo; H Grosfeld; D S Stec
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

4.  A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.

Authors:  J E Crowe; P T Bui; A R Davis; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

5.  The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.

Authors:  K Juhasz; S S Whitehead; C A Boulanger; C Y Firestone; P L Collins; B R Murphy
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

6.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

7.  Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.

Authors:  C Y Firestone; S S Whitehead; P L Collins; B R Murphy; J E Crowe
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

8.  Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.

Authors:  J E Crowe; P T Bui; W T London; A R Davis; P P Hung; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1994-06       Impact factor: 3.641

9.  Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

Authors:  J E Crowe
Journal:  Vaccine       Date:  1995-03       Impact factor: 3.641

10.  Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.

Authors:  J E Crowe; P T Bui; G R Siber; W R Elkins; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1995-06       Impact factor: 3.641

View more
  9 in total

Review 1.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

2.  Fidelity of leader and trailer sequence usage by the respiratory syncytial virus and avian pneumovirus replication complexes.

Authors:  A C Marriott; J M Smith; A J Easton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 3.  Progress in the development of human parainfluenza virus vaccines.

Authors:  Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins
Journal:  Expert Rev Respir Med       Date:  2011-08       Impact factor: 3.772

4.  Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66.

Authors:  Erich Hoffmann; Kutubuddin Mahmood; Zhongying Chen; Chin-Fen Yang; Joshua Spaete; Harry B Greenberg; M Louise Herlocher; Hong Jin; George Kemble
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

6.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Identification of a single amino acid change in the human respiratory syncytial virus L protein that affects transcriptional termination.

Authors:  Tara L Cartee; A George Megaw; A G P Oomens; Gail W Wertz
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  Model-based design of growth-attenuated viruses.

Authors:  Kwang-Il Lim; Tobias Lang; Vy Lam; John Yin
Journal:  PLoS Comput Biol       Date:  2006-07-24       Impact factor: 4.475

9.  GDP polyribonucleotidyltransferase domain of vesicular stomatitis virus polymerase regulates leader-promoter escape and polyadenylation-coupled termination during stop-start transcription.

Authors:  Minako Ogino; Todd J Green; Tomoaki Ogino
Journal:  PLoS Pathog       Date:  2022-02-02       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.